Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + lenvatinib + TACE vs TACE in unresectable non-metastatic hepatocellular carcinoma
ChiCTR2400087138Phase 3Recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Jul 2024
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Cadonilimab + lenvatinib + TACE, Double placebo + TACE and Cadonilimab + placebo for lenvatinib + TACE (3 arms). Primary endpoint: Progression-free survival (PFS). Started Jul 2024; status: recruiting.
02
Drugs
cadonilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400087138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087138.